Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended): A method for preventing a viral infection in a mammal, said method comprising: administering a pharmaceutically effective amount of a liposomal formulation to said mammal, wherein said liposomal formulation comprises:

a) a lipid vesicle; and

b) ~~a fatty acid monoglyceride~~ an active agent for preventing said viral infection of formula:



wherein R^1 or R^2 is [[a]] an ~~C_2-C_{18} alkyl~~ octyl group and the other is hydrogen; and,

wherein said viral infection is caused by ~~an enveloped virus~~ HSV or HIV.

2-5. (Canceled)

6. (Withdrawn): The method of claim **1**, wherein said enveloped virus is selected from the group consisting of VSV, VV, MV, HSV, and HIV.

7. (Withdrawn): The method of claim **1**, wherein said infection is a bacterial infection.

8. (Withdrawn): The method of claim **7**, wherein said bacterial infection is selected from the group consisting of Gonorrhea and Chlamydia.

9. (Withdrawn): The method of claim **1**, wherein said infection is a parasitic protozoan infection.

10. (Withdrawn): The method of claim **7**, wherein said protozoa is Giardia lamblia.

11. (Withdrawn): The method of claim **1**, wherein said formulation is selected from the group consisting of a topical formulation, an oral formulation, a nasal formulation, an ophthalmic formulation, a rectal formulation, vaginal formulation, and parenteral formulation.

12. (Withdrawn): A liposomal formulation comprising:

a) a lipid vesicle; and

b) at least one single chain lipid active agent.

13. (Withdrawn): The liposomal formulation of claim **12**, wherein said active agent is selected from the group consisting of a monoglyceride, a fatty acid, a lysophospholipid, and a combination thereof.

14. (Withdrawn): The liposomal formulation of claim **13**, wherein said active agent is a monoglyceride.

15. (Withdrawn): The liposomal formulation of claim **14**, wherein said monoglyceride is a monoalkyletherglyceride with a number of carbon atoms in the alkyl moiety portion being from about 2 to about 18.

16. (Withdrawn): The liposomal formulation of claim **15**, wherein said monoglyceride is selected from the group consisting of 1 O-alkyl-sn-glycerol, 2-O-alkyl-sn-glycerol, and a mixture thereof.

17. (Withdrawn): The liposomal formulation of claim **16**, wherein said monoglyceride is 1-O-octyl-sn-glycerol, 2-O-octyl-sn-glycerol, and a mixture thereof.

18. (Withdrawn): The liposomal formulation of claim **14**, wherein said monoglyceride is a single chain fatty acid monoglycerides with a number of carbon atoms in the fatty acid moiety portion being from about 6 and about 12.

19. (Withdrawn): The liposomal formulation of claim **12**, wherein said lipid vesicle comprises a phospholipids.

20. (Withdrawn): The liposomal formulation of claim **19**, wherein said phospholipid is phosphatidylcholine.

21. (Withdrawn): The liposomal formulation of claim **20**, wherein said lipid vesicle further comprises a diluent selected from the group consisting of a co-solvent, a buffer solution, an anti-oxidant, a preservative, a thickening agent and a mixture thereof.

22. (Withdrawn): The liposomal formulation of claim **21**, wherein said co-solvent comprises propylene glycol, ethanol, water or mixtures thereof.

23. (Withdrawn): The liposomal formulation of claim **21**, wherein said anti-oxidant comprises vitamin E acetate.

24. (Withdrawn): The liposomal formulation of claim **21**, wherein said preservative comprises methylparaben, propylparaben or mixtures thereof.

25. (Withdrawn): The liposomal formulation of claim **21**, wherein said thickening agent comprises Carbopol, Crothix or mixtures thereof.

26. (Withdrawn): The liposomal formulation of claim **12**, wherein said lipid vesicle is unilamellar.

27. (Withdrawn): The liposomal formulation of claim **12**, wherein said lipid vesicle is multilamellar.

28. (Withdrawn): The liposomal formulation of claim **12**, wherein said lipid vesicle is oligolamellar.

29. (Withdrawn): The liposomal formulation of claim **12**, wherein said lipid vesicle comprises a co-lipid.

30. (Withdrawn): The liposomal formulation of claim **29**, wherein said co-lipid is selected from the group consisting of a cholesterol, a phospholipid, a cationic lipid, an anionic lipid, and a combination thereof.

31. (Withdrawn): The liposomal formulation of claim **30**, wherein said cationic lipid is selected from the group consisting of stearyl-amine, DC-Chol, DOTAP, and a combination thereof.

32. (Withdrawn): The liposomal formulation of claim **30**, wherein said anionic lipid is selected from the group consisting of PS, PG, and a combination thereof.

33. (Withdrawn): The liposomal formulation of claim **12**, wherein said formulation is a topical formulation.

34. (Withdrawn): The liposomal formulation of claim **33**, wherein said topical formulation is selected from the group consisting of cream, a gel, a lotion, a suppository, a fluid suspension, and a paste.

35. (Withdrawn): The liposomal formulation of claim **12**, wherein said active agent is encapsulated by the lipid vesicle.

36. (Withdrawn): A pharmaceutical composition comprising:

a pharmaceutical excipient; and

a liposomal formulation comprising a lipid vesicle and at least one single chain lipid active agent.

37. (Withdrawn): The composition of claim **36**, wherein said excipient comprises an antioxidant, a co-solvent, a preservative, a flavoring agent, vitamin, a thickening agent, a buffer solution, a wetting agent, an emulsifying agent, a suspending agent, a sweetening agent, a flavoring agent, a perfuming agent or mixtures thereof.

38. (Withdrawn): The method of claim **1**, wherein said C_2-C_{18} alkyl group is a C_6-C_{12} alkyl group.

39. (Currently amended): The method of claim [[**38**]] **1**, wherein said ~~fatty acid monoglyceride~~ active agent is 1-O-octyl-sn-glycerol ~~or 2-O-octyl-sn-glycerol~~.

40. (Withdrawn): The method of claim **39**, wherein said enveloped virus is selected from the group consisting of VSV, VV, MV, HSV, and HIV.

41. (Withdrawn): The method of claim **40**, wherein said formulation is selected from the group consisting of a topical formulation, an oral formulation, a nasal formulation, an ophthalmic formulation, a rectal formulation, vaginal formulation, and parenteral formulation.

42. (New): The method of claim **1**, wherein said active agent is 2-O-octyl-sn-glycerol.